Innate Pharma: The Deal That Was Always "Coming" Finally Landed

A $75M Sobi upfront plus a €30M raise turn a two-quarter cash story into a six-quarter one — and both PACIFIC-9 and the first IPH4502 dataset are due within months.

IPH.PA · Earnings Call · 2026-09-17

The deal that kept slipping finally closed

For three straight quarters, the most-asked question on Innate Pharma's calls was whether a partner would ever be signed for lacutamab. Management kept saying it was close without naming anyone. In September 2025 the framing was keeping options open for both investors and potential partners; by March 2026, BTIG's Jeet Mukherjee was asking again and CEO Jonathan Dickinson told him “watch this space, and we should hopefully make a decision in the not-too-distant future.” — Jonathan Dickinson, Chief Executive Officer · 2026-03-26 In May 2026, Dickinson was still “very confident that we will execute either a BD partnership or a royalty financing partnership for lacutamab.” — Jonathan Dickinson, Chief Executive Officer · 2026-05-13 It finally closed. The strategic partnership with Sobi (rendered "Sobe" in parts of the transcript) was signed in August and became effective the day before this call. TELLOMAK-3, the confirmatory Phase 3 in cutaneous T-cell lymphoma, has been initiated, with first patient targeted for Q1 2027 and an accelerated approval filing in Sézary syndrome planned for H2 2027.

Under the terms of the agreement, the transaction includes a 75 million upfront payment up to 40 million in near term milestones connected to Sezary Syndrome. And up to an additional $465 million related to Sobe's option to obtain full development rights and future regulatory and commercial milestones. Agreement also includes tiered double digit royalties on future net sales.
Jonathan E. Dickinson, Chief Executive Officer · 2026-09-17

That is the first genuinely new thing here. For a company whose entire investment case rested on "we'll decide in the not-too-distant future," the decision is now made, part of the cash is a contractual claim, and the Phase 3 clock is running.

A balance sheet rebuilt, quietly

The second change is financial, and for a $184M-market-cap name it may matter more. As of June 30, 2026, Innate held €21.4M in cash and financial assets — roughly two quarters of life on the old plan. Two weeks before the call, the company raised €30M gross (€28M net), and the balance sheet now also absorbs the $75M Sobi upfront payment, worth about €65M. CFO Frederic Lombard framed it plainly: “Together with the Sobe upfront payment, these proceeds are expected to extend our cash runway through the end of the first quarter of 2028.” — Frederic Lombard, Chief Financial Officer · 2026-09-17 The contrast with a year ago is stark. On the September 2025 call, asked about the cash runway, Lombard said:

The answer to that is yes. So the restructuring plan is fully embedded into the cash runway, which takes us to the end of Q3 2026.
Jonathan Dickinson · 2025-09-17

Same company, same question, roughly eighteen extra months of funding — the difference between a financing overhang and a genuine option. The equity financing was also unusually well specified: proceeds are earmarked for IPH4502's clinical development, the preclinical ADC portfolio, and general corporate purposes. In Q&A, Dickinson was explicit that the raise buys "the initial steps" for IPH4502 — dose optimization — and that broadening into multiple tumor types would need more money. That is honest capital allocation at this size.

IPH4502 is where the tape's money already sits

The asset carrying the most optionality is IPH4502, a Nectin-4 exatecan ADC. Management reported completing dose escalation and cohort enrichment enrollment, with objective responses in heavily pretreated patients. CMO Sonia Quaratino: “We have observed preliminary antitumor activity with objective responses in heavily pretreated patients, including patients with urothelial cancer following prior enfortumab vedotin treatment as well as in non small cell lung cancer, head and neck cancer.” — Sonia Quaratino, Chief Medical Officer · 2026-09-17 The disclosure lands at the EORTC-NCI-AACR meeting on November 18 in Barcelona. It is worth being disciplined about what this is. Quaratino, asked whether the dataset would be safety-only or development-informing, answered “this is out of 11 different indications and 76 patients,” — Sonia Quaratino, Chief Medical Officer · 2026-09-17 with roughly 15 patients each in post-EV urothelial and head and neck cancer and lighter enrollment in non small cell lung cancer. That is a real dataset, not a teaser — but still early, and "data cleaning is ongoing." The market's theme tape is already leaning this way: dose escalation and Phase 1 study rank among the strongest-performing baskets in Know Trend's 360-day theme movers, with the dose-escalation cluster persisting as a 90-day advancer. Innate is riding a genuinely bid cohort of early-stage oncology readouts — though as a micro-cap with no price tape supplied here, it may not capture the same multiple.

Three catalysts — and what quietly fell off

Dickinson closed with the punchline: “we have 3 important near term catalysts across our focus portfolio.” — Jonathan E. Dickinson, Chief Executive Officer · 2026-09-17 The largest is the PACIFIC-9 Phase 3 readout for monalizumab in Stage III NSCLC, expected in H2 2026 — effectively any week now — with AstraZeneca expected to press-release first. Innate has already banked $450M from that partnership, with up to $825M more in milestones plus double-digit royalties and 50% European profit sharing. It is the rare case of a near-term binary the company does not have to fund. Meanwhile, the themes that dominated Innate's 2024 keyword lists — ANKET/NK-cell engagers and the MATISSE/CD39 program — have dropped off the current top-30 entirely. That is no accident: management has said the NK engagers are "not our priority today" and has funnelled the organization behind lacutamab, IPH4502 and monalizumab. The narrowing is a feature, not a bug, and Sobi's cash is what makes it affordable. Against a global keyword backdrop dominated this quarter by tariff refunds and earnings growth, Innate's story is entirely idiosyncratic — which is precisely the point. The change this quarter is not a new science narrative; it is that a promise became a contract, a two-quarter runway became a six-quarter one, and a Phase 1 dataset now has a date on it.